# QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes

> **NCT01474018** · PHASE4 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 15 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** QR-bromocriptine

## Key facts

- **NCT ID:** NCT01474018
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-05
- **Final completion:** 2012-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01474018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01474018, "QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01474018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*